Re: Jonas Hugosson, Monique J. Roobol, Marianne Månsson, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2019;76:43-51 (European Urology)

In their paper on prostate cancer (PCa) mortality and prostate-specific antigen (PSA) screening, Hugosson et al [1] conclude `Findings corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level.` The patient description states `... repeated screening reduces the risk of dying from prostate cancer`.